SRTA - Strata Critical Medical Announces Second Quarter 2026 Results

On Tuesday, Strata Critical Medical (NASDAQ: SRTA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. Access the full call at Summary Strata Critical Medical reported strong Q2 2026 results with a 15.1% sequential growth in clinical revenue, driven by 23.8% growth in transplant clinical revenue and an increase in clinical gross margins to 26.1%. The company executed three strategic acquisitions during Q2, enhancing its clinical footprint and operational efficiency, contributing over $20 million in revenue and $6.3 million in projected annualized adjusted EBITDA. Guidance for 2026 was increased to $285-$295 million in revenue and $33-$35 million in adjusted EBITDA, reflecting accelerated clinical growth and acquisitions, despite short-term logistics margin headwinds. Logistics revenue faced a 3% headwind due to a reduction in flying with a non-exclusive customer, but recovery is expected by Q4 2026. Initiatives are underway to restore logistics gross margins to 20% by 2027. The company's strategic shift towards clinical services, combined with its M&A strategy, positions it for long-term success with a more diversified business and increased cash generation capabilities. Full Transcript Matt, Investor Relations Statements about future time periods may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC, for a more detailed discussion of the risk factors that could cause these differences. Any forward-looking statements provided during this conference call are made only as of the date of this call, as stated in their SEC filings. Strata Critical Medical disclaims any intent or obligation to update or revise these forward-looking statements except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly comparable historical consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release, investor presentation, and Forms 10-Q and 10-K filings are available on the Investor Relations section of our website at ir.stratacritical.com. These non-GAAP measures should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa T